In a new clinical trial of non-diabetic subjects older than 50 years, US-based DolCas Biotech, LLC’s Bergacyn FF® demonstrated an ability to help reduce liver fat and body weight. This hallmark study follows a previous investigation that supported Bergacyn’s liver-fat lowering effects in subjects with diabetes while providing extra cardioprotective support.
The study was conducted at the University Magna Grecia, Catanzaro, Italy, and published on August 11, 2020, in the journal Frontiers in Endocrinology. A total of 102 mildly hypercholesterolemic patients, age 35-70 and with liver steatosis were enrolled in a double-blind placebo-controlled clinical trial and randomized to receive 600 mg/d of either Bergacyn FF or a maltodextrin-based placebo.
The results of the study revealed that liver fat accumulation was reduced by 9% over the placebo group. Bergacyn FF also produced a significant positive factor in its potential to regress the progression of fatty liver. Notably, in those subjects over 50 years of age, the reduction in liver fat was even more remarkable at 15% greater than the placebo and was attributed solely to Bergacyn FF, and not the dietary changes.
Bergacyn FF produced more profound benefits over placebo not only for subjects older than 50, but for women and overweight/obese persons.
Bergacyn FF, is a clean-label powerhouse blend of botanical extracts derived from the Italian bergamot citrus fruit (Citrus bergamia) and the wild Italian artichoke thistle leaf (Cynara cardunculus sylvestris). The new patented formulation is free of any solvents or excipients and the Bergamot juice and pulp serve as upcycled source materials to provide the polyphenols and fiber in Bergacyn FF.